Results 121 to 130 of about 117,912 (291)

Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review

Lymphatic Research and Biology, 2018
Background: Extensive lymphatic malformations are low-flow vascular malformations that can cause devastating complications. Treatment of these malformations is challenging.
S. Wiegand, G. Wichmann, A. Dietz
semanticscholar   +1 more source

Application of sirolimus in an infant presenting with a life-threatening lymphatic malformation of the head and neck: a case report

Frontiers in Pediatrics
Extensive lymphatic malformations in the head and neck region pose a significant risk due to potential airway compression, and conventional treatment modalities have proven largely ineffective.
Shuying Yu, Xiaowen Guo
doaj   +1 more source

Tacrolimus rescue therapy for renal allograft rejection - Five-year experience [PDF]

, 1997
Over the 5 year period from 7/14/1989 until 5/24/1994, we have attempted graft salvage with tacrolimus conversion in a total of 169 patients (median age 33 years, range 2-75 years) with ongoing rejection on baseline CsA immunosuppression after failure of
Demetris, AJ, Fung, JJ, Gritsch, HA, Jordan, ML, McCauley, J, McMichael, J, Naraghi, R, Randhawa, P, Scantlebury, VP, Shapiro, R, Smith, D, Starzl, TE, Vivas, CA   +12 more
core   +1 more source

A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims To explore UK key‐opinion leader perspectives on the future role of stem cell‐derived islets (sc‐islets) in islet transplantation for people with type 1 diabetes (T1D). Methods Four UK‐based key‐opinion leaders evaluated current limitations of donor islet transplantation and reviewed emerging evidence, clinical pathways and logistical ...
Thomas Strakosch, Shareen Forbes
wiley   +1 more source

PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells [PDF]

, 2019
Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR).
Althoff, Till F., Burghaus, Jana, Cao Ho, Thanh, Jürgensen, Lonny, Kamuf-Schenk, Verena, Katus, Hugo A., Kiper, Leon, Krull, Alexandros, Riechert, Eva, Schecker, Johannes, Stangl, Karl, Stangl, Verena, Völkers, Mirko, Wöltje, Kerstin, Zhang, Kevin Sun   +14 more
core   +1 more source

Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501.

Blood, 2019
Clinical- and biomarker-based tools may identify a lower risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced intensity treatments. Previous data suggest sirolimus may rival standard of care prednisone.
J. Pidala, M. Hamadani, P. Dawson, M. Martens, A. Alousi, M. Jagasia, Y. Efebera, S. Chhabra, I. Pusic, S. Holtan, J. Ferrara, J. Levine, M. Mielcarek, C. Anasetti, J. Antin, J. Bolaños-Meade, Alan Howard, B. Logan, E. Leifer, T. Pritchard, M. Horowitz, M. MacMillan   +21 more
semanticscholar   +1 more source

Clinical outcomes following stereotactic MRI‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In children with tuberous sclerosis complex (TSC) and drug‐resistant epilepsy (DRE), magnetic resonance imaging–guided stereotactic laser ablation (SLA) therapy offers less‐invasive treatment compared to craniotomy and resection. Our study seeks to further expand on the long‐term outcomes in patients with TSC‐related DRE who have ...
Chelsey Ortman, Rohini Coorg, Irfan Ali, Dave Clarke, Gloria Diaz‐Medina, Kimberly Houck, Akshat Katyayan, Laura Masters, Deepankar Mohanty, Anuranjita Nayak, Michael Quach, Vijay M. Ravindra, James J. Riviello, Sonali Sen, Elaine Seto, Danielle Takacs, Cristina Trandafir, John T. Freiling, Karen Evankovich, Yingchao Yuan, Kalman A. Katlowitz, Daniel Curry, Howard L. Weiner, Anne Anderson   +23 more
wiley   +1 more source

A simple and robust method for connecting small-molecule drugs using gene-expression signatures [PDF]

, 2008
Interaction of a drug or chemical with a biological system can result in a gene-expression profile or signature characteristic of the event. Using a suitably robust algorithm these signatures can potentially be used to connect molecules with similar ...
B Efron, CC Ting, J Frasor, J Lamb, JD Storey, JJ Chen, JS Warrington, KB Glaser, L Tian, M Lee, N Fujimoto, N Sathyamoorthy, PA Horwitz, R Januchowski, S McHugh, SD Zhang, Shu-Dong Zhang, ST Matalon, Timothy W Gant, VW Armstrong, Y Chen   +20 more
core   +5 more sources

Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus

Hepatology, 2019
As conversion from calcineurin inhibitor to sirolimus (SRL), a mechanistic target of rapamycin inhibitor (mTOR‐I), has been shown to enhance immunoregulatory profiles in liver transplant (LT) recipients (LTRs), mTOR‐I therapy might allow for increased ...
J. Levitsky, B. Burrell, S. Kanaparthi, L. Turka, S. Kurian, A. Sánchez‐Fueyo, J. Lozano, A. Demetris, Andrew Lesniak, A. Kirk, L. Stempora, Guang-Yu Yang, J. Mathew   +12 more
semanticscholar   +1 more source

Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

International Journal of Dermatology, EarlyView.
Meta‐analysis of randomized controlled trials shows that switching from calcineurin inhibitors (CNI) to sirolimus in kidney transplant recipients (KTRs) with prior cutaneous squamous cell carcinoma (cSCC) reduces secondary cSCC incidence but increases adverse‐event–related treatment discontinuation.
Yannick Foerster, Julia Palaras, Kristine Mayer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source